Evidence map›Paper›PMID 41629462›Full record

ArticleNature biotechnology2026

Customizing CRISPR-Cas PAM specificity with protein language models.

Stephen Nayfach, Aadyot Bhatnagar, Andrey Novichkov, Nahye Kim, Alexander M Hoffnagle, Riffat Hussain, Gabriella O Estevam, Emily Hill, Jeffrey A Ruffolo, Rachel A Silverstein and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Stephen NayfachProfluent Bio, Emeryville, CA, USA. snayfach@profluent.bio.ORCID http://orcid.org/0000-0003-4625-4164
Aadyot BhatnagarProfluent Bio, Emeryville, CA, USA.
Andrey NovichkovProfluent Bio, Emeryville, CA, USA.
Nahye KimCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Alexander M HoffnagleProfluent Bio, Emeryville, CA, USA.
Riffat HussainProfluent Bio, Emeryville, CA, USA.
Gabriella O EstevamProfluent Bio, Emeryville, CA, USA.
Emily HillProfluent Bio, Emeryville, CA, USA.
Jeffrey A RuffoloProfluent Bio, Emeryville, CA, USA.ORCID http://orcid.org/0000-0002-3385-9191
Rachel A SilversteinCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Joseph GallagherProfluent Bio, Emeryville, CA, USA.
Benjamin P KleinstiverCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5469-0655
Alexander J MeeskeProfluent Bio, Emeryville, CA, USA.
Peter CameronProfluent Bio, Emeryville, CA, USA.
Ali MadaniProfluent Bio, Emeryville, CA, USA. ali@profluent.bio.ORCID http://orcid.org/0000-0002-3092-1295

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR-Cas enzymes must recognize a protospacer-adjacent motif (PAM) to edit a genomic site, greatly limiting the range of targetable sequences in a genome. Although engineering strategies to alter PAM specificity exist, they typically require labor-intensive, iterative experimentation. We introduce an evolution-informed deep learning model, Protein2PAM, to efficiently guide the design of Cas protein variants tailored to recognize specific PAMs. Trained on a dataset of over 45,000 CRISPR-Cas PAMs, Protein2PAM rapidly and accurately predicts PAM specificity directly from Cas proteins across type I, II and V CRISPR-Cas systems. Using in silico mutagenesis, the model identifies residues critical for PAM recognition in Cas9 without using structural information. We use Protein2PAM to computationally evolve Nme1Cas9, generating variants with broadened PAM recognition and up to a 50-fold increase in PAM cleavage rates compared to the wild type in vitro. Our machine learning approach allows Cas enzymes to target sequences that were previously inaccessible because of PAM constraints, potentially increasing target flexibility in personalized genome editing.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.